MedPath

Clinical Trial News

AstraZeneca's AZD1390 to be Evaluated in GBM AGILE Trial for Glioblastoma

  • AstraZeneca's AZD1390 will be evaluated in the Glioblastoma Adaptive Global Innovative Learning Environment (GBM AGILE) trial, a global adaptive platform.
  • The trial, designed with response adaptive randomization and a Phase II/III structure, aims to accelerate the identification of effective glioblastoma therapies.
  • AZD1390 arm will focus on newly diagnosed glioblastoma patients, with recruitment anticipated to commence in the second quarter of next year.
  • GBM AGILE, operating under a master protocol, allows concurrent evaluation of multiple treatments against a common control arm.

FDA Approves BridgeBio's Attruby (acoramidis) for Transthyretin Amyloid Cardiomyopathy

• The FDA has approved BridgeBio Pharma's Attruby (acoramidis) for treating transthyretin amyloid cardiomyopathy (ATTR-CM) in adults, marking a significant advancement in cardiac care. • Attruby is the first approved therapy with a label indicating near-complete transthyretin (TTR) stabilization, aiming to reduce cardiovascular deaths and hospitalizations associated with ATTR-CM. • The approval was based on the Phase III ATTRibute-CM trial, which demonstrated a statistically significant impact on all-cause mortality, cardiovascular hospitalizations, and functional capacity. • BridgeBio plans to seek approvals globally, including in Europe, Japan, and Brazil, and will provide Attruby free for life to US trial participants as a gesture of gratitude.

Cenerimod Demonstrates Reduced Interferon Signatures in Phase 2b SLE Trial

  • Cenerimod 4 mg significantly reduced interferon (IFN)-associated protein and gene signature biomarkers in SLE patients after 6 months compared to placebo.
  • The 4 mg dose showed a more pronounced effect on IFN-1, IFN-γ, and plasma cell biomarkers compared to the 2 mg dose.
  • Cenerimod 4 mg prevented the transition from low to high IFN-1 status in patients with SLE, indicating a potential disease-modifying effect.
  • The findings support the rationale for using cenerimod 4 mg in Phase 3 clinical trials for moderate to severe SLE.

Efficacy and Safety of Four Doses of Cenerimod Compared to Placebo in Adult Subjects With Active Systemic Lupus Erythematosus

NCT03742037CompletedPhase 2
Idorsia Pharmaceuticals Ltd.
Posted 12/21/2018

Electronic Tool Streamlines Stroke Patient Screening for Clinical Trials

  • An electronic tool, the stroke trial tracker, has been developed to streamline the screening and management of stroke patients for clinical trial eligibility.
  • The implementation of the tool has reduced screening time by over 80%, freeing up nurses' time for recruitment activities and increasing patient involvement in trials.
  • The electronic system minimizes human error, enhances efficiency, prevents redundant patient approaches, and improves overall team communication and data accuracy.
  • A survey of UK stroke centers indicates a strong interest in adopting similar systems to save time and improve the accuracy of patient screening for research studies.

FDA Approves BridgeBio's Attruby (acoramidis) for ATTR-CM Treatment

• The FDA has approved BridgeBio Pharma's Attruby (acoramidis) for treating transthyretin amyloid cardiomyopathy (ATTR-CM) in adults, marking a significant advancement in cardiac care. • Attruby, an oral transthyretin (TTR) stabilizer, is the first approved product with a label specifying near-complete TTR stabilization, reducing cardiovascular deaths and hospitalizations. • The approval was based on the Phase III ATTRibute-CM trial, which demonstrated a win ratio of 1.8 and significant improvements in the six-minute walk test and NT-proBNP levels. • BridgeBio plans to pursue global approvals and provide Attruby free for life to US trial participants, with Bayer holding exclusive commercialization rights in Europe.

FDA Accepts GSK's Blenrep Combination Therapy for Relapsed/Refractory Multiple Myeloma

  • The FDA has accepted GSK's biologics license application for Blenrep in combination with BorDex and PomDex.
  • This combination therapy targets patients with relapsed or refractory multiple myeloma who have undergone at least one prior line of therapy.
  • The FDA's decision is expected by July 23, with the application based on positive results from the DREAMM-7 and DREAMM-8 phase III trials.
  • Multiple myeloma is the third most common type of blood cancer, with a need for new therapies due to resistance to available treatments.

Care Bundles Improve Enteral Nutrition Management in Stroke Patients: A Multi-Center Trial

  • A multi-center, stepped-wedge, cluster-based randomized controlled trial is underway to evaluate care bundles for enteral nutrition in stroke patients.
  • The primary hypothesis is that these care bundles will reduce feeding intolerance, a common and serious complication in stroke patients requiring nutritional support.
  • Secondary hypotheses include reduced complications, improved nutritional status, and better overall recovery for stroke patients receiving the intervention.
  • The trial involves eight hospitals in China, with a target sample size of 1224 patients, aiming to demonstrate the effectiveness of standardized enteral nutrition protocols.

FDA to Review Belantamab Mafodotin and Linvoseltamab Combinations for Multiple Myeloma

  • The FDA has accepted a BLA for belantamab mafodotin combinations with bortezomib plus dexamethasone and pomalidomide plus dexamethasone for multiple myeloma treatment.
  • Regeneron's linvoseltamab BLA resubmission has been accepted by the FDA, with a decision expected by July 10, 2025, for relapsed/refractory multiple myeloma.
  • Clinical trials DREAMM-7 and DREAMM-8 support the belantamab mafodotin BLA, while LINKER-MM1 supports the linvoseltamab BLA, showcasing improved progression-free survival.
  • Both belantamab mafodotin and linvoseltamab are under review by other regulatory authorities, potentially expanding treatment options for multiple myeloma patients.

A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Participants With Follicular Lymphoma

NCT06091254RecruitingPhase 3
Regeneron Pharmaceuticals
Posted 12/12/2023

Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN)

NCT04501666CompletedPhase 3
Galderma R&D
Posted 9/11/2020

A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma

NCT05730036RecruitingPhase 3
Regeneron Pharmaceuticals
Posted 9/18/2023

A Trial to Learn if Odronextamab Combined With Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Chemotherapy for Adult Participants With Follicular Lymphoma

NCT06097364RecruitingPhase 3
Regeneron Pharmaceuticals
Posted 11/14/2023

A Study to Assess the Anti-Tumor Activity and Safety of Odronextamab in Adult Patients With B-cell Non-Hodgkin Lymphoma Who Have Been Previously Treated With Other Cancer Therapies

NCT03888105RecruitingPhase 2
Regeneron Pharmaceuticals
Posted 11/13/2019

Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma

NCT04246047Active, Not RecruitingPhase 3
GlaxoSmithKline
Posted 5/7/2020

Phase 1/2 Study of REGN5458 in Adult Patients With Relapsed or Refractory Multiple Myeloma

NCT03761108RecruitingPhase 1
Regeneron Pharmaceuticals
Posted 1/23/2019

Study to Investigate the Safety and Tolerability of Odronextamab in Patients With CD20+ B-Cell Malignancies

NCT02290951Active, Not RecruitingPhase 1
Regeneron Pharmaceuticals
Posted 1/9/2015

Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma

NCT04484623Active, Not RecruitingPhase 3
GlaxoSmithKline
Posted 10/1/2020

A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Patients With Multiple Myeloma That is Resistant to Current Standard of Care Treatments

NCT05137054RecruitingPhase 1
Regeneron Pharmaceuticals
Posted 8/17/2022

Injectable Oxygen Microbubbles Show Promise in Treating Hypoxemia and Preventing Organ Damage

  • Researchers have developed injectable oxygen microbubbles for rapid oxygen delivery during critical moments of cardiac or respiratory arrest, addressing the limitations of traditional methods.
  • In preclinical testing, pH-sensitive microbubbles delivered precise amounts of oxygen, significantly improving survival and preventing catastrophic organ damage in hypoxemic conditions.
  • The microbubbles are engineered with a solid-like polymer shell that dissolves into tiny soluble molecules when triggered by blood pH, ensuring rapid dissolution and preventing blood-flow obstruction.
  • This innovative approach represents a potential platform technology for delivering various gases in focused amounts, opening possibilities for treating other medical conditions beyond hypoxemia.

Novartis' Scemblix Shows Promising 96-Week Data in First-Line CML Treatment

• Scemblix (asciminib) demonstrates favorable safety and tolerability compared to investigator-selected TKIs in newly diagnosed CML-CP patients. • The ASC4FIRST Phase III study's 96-week results support Scemblix as a potential first-line treatment option for chronic myeloid leukemia. • Novartis is presenting over 65 abstracts at ASH and SABCS, highlighting their commitment to cancer and blood disorder research.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.